Company Overview of ContraVir Pharmaceuticals, Inc.
ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. Its lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus. The company has completed Phase I trials of FV-100 in volunteers, as well as a Phase IIa clinical trial in shingles patients. It also plans to conduct a trial in patients with shingles to further explore FV-100's potential to treat the long-lasting nerve pain typically associated with shingles. The company was founded in 201...
399 Thornall Street
Edison, NJ 08837
Founded in 2013
Key Executives for ContraVir Pharmaceuticals, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $86.2K
Chief Financial Officer
Total Annual Compensation: $4.9K
Compensation as of Fiscal Year 2014.
ContraVir Pharmaceuticals, Inc. Key Developments
ContraVir Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 04:00 PM
Jun 8 15
ContraVir Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 04:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: James E. Sapirstein, Chief Executive Officer and Director.
ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
Mar 9 15
ContraVir Pharmaceuticals, Inc. announced the outcome of a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding the company's lead drug candidate, FV-100, for the prevention of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). The FDA has agreed to, with minor modifications, ContraVir's proposed clinical protocol, which is designed as a pivotal Phase 3 study. While antivirals are approved to treat the viral infection underlying shingles, there are currently no approved antiviral therapies for preventing PHN. It remains a major unmet medical need, and ContraVir has been exploring the potential of FV-100 to prevent the severe and long-lasting effects of this condition. The Phase 3 study will build upon prior clinical results for FV-100, including Phase 1 trials as well as a large Phase 2 clinical trial in shingles patients, which demonstrated excellent safety and tolerability for FV-100.
ContraVir Pharmaceuticals Seeks Acquisitions
Mar 9 15
ContraVir Pharmaceuticals, Inc. (NasdaqCM:CTRV) intends to use the net proceeds to repay any debts and/or invest in or acquire complementary businesses, products or technologies, although they have no current commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 26, 2015
October 14, 2014